CERo Therapeutics Holdings, Inc. (CERO): חוב להון עצמי

CERo Therapeutics acts as a biopharmaceutical pioneer, creating a unique T-cell reprogramming system to combat tumors without harming the body. The asset's market value, as illustrated on this chart, confirms a risk-minimization strategy through the development of methods to stimulate immunity against blood cancer, while the total debt-to-equity ratio stands at 0.00. High research intensity in preparation for T-Chime clinical trials guarantees a powerful scientific and technological breakthrough.

The debt_total_eq_co ratio measures the proportion of borrowed liabilities within the equity structure, determining the degree of financial autonomy and debt load risk. The current debt-to-equity ratio of 0.00 is critically important for CERo Therapeutics (CERO), as low leverage provides the resource base necessary for scaling universal cell-based cancer treatment technologies and ensures long-term business sustainability.